Hangzhou Purui Life Technology

About Hangzhou Purui Life Technology

Hangzhou Purui Life Technology, also known as Primelife Science, is a technology firm specializing in digital solutions for the life sciences sector. The company provides an integrated platform that automates and streamlines the entire clinical research lifecycle, from trial execution to data analysis and strategic decision-making. Its core offering is a Digitalized Clinical Operation Solution (DCOs) designed to enhance the efficiency, data quality, and compliance of clinical trials for biopharmaceutical and medical device companies.

Founded in Hangzhou in January 2021, Purui was established in response to the operational bottlenecks in traditional clinical research, a need amplified by the COVID-19 pandemic. The company was co-founded by the global contract research organization (CRO) giant IQVIA, which provides significant technological, operational, and commercial support, positioning Purui as its strategic incubated enterprise in China. The firm has secured substantial funding to support its growth, including a 100 million RMB Pre-A round in early 2022 and a nearly 100 million RMB Pre-A+ round in 2023.

The company's founder and CEO is Wang Zheng, who brings a unique blend of medical and business expertise to the firm. Wang is a medical doctor with a background as a cardiac surgeon, holds an MBA from Duke University, and previously managed strategy and investments for IQVIA in the Asia-Pacific region. His vision was to create a company that combines a global perspective on clinical standards with localized digital innovation to serve the rapidly expanding Chinese biopharmaceutical market. The founding team is comprised of professionals with experience from leading companies such as IQVIA, Google, and Pfizer.

Purui's flagship product is its E2E platform, the first in China built on end-to-end EMR-to-EDC (Electronic Medical Record to Electronic Data Capture) technology. This system automates the transfer of clinical data from hospital records to research databases, utilizing AI and natural language processing to ensure data is accurate, complete, and standardized. This significantly reduces manual data entry, enables remote monitoring, and ensures a verifiable audit trail, which helps clients meet the stringent regulatory standards of the NMPA, FDA, and EMA for multi-center international trials. The company serves pharmaceutical developers, research hospitals, and government agencies, aiming to become a key technology provider that bridges China's clinical research industry with the global ecosystem.